| 001 | 272852 | ||
| 005 | 20241029085454.0 | ||
| 024 | 7 | _ | |a 10.1002/mds.29879 |2 doi |
| 024 | 7 | _ | |a pmid:38847384 |2 pmid |
| 024 | 7 | _ | |a 0885-3185 |2 ISSN |
| 024 | 7 | _ | |a 1531-8257 |2 ISSN |
| 024 | 7 | _ | |a altmetric:164390137 |2 altmetric |
| 037 | _ | _ | |a DZNE-2024-01270 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Jensen, Ida Marie Louise |0 P:(DE-2719)9003066 |b 0 |u dzne |
| 245 | _ | _ | |a Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria. |
| 260 | _ | _ | |a New York, NY |c 2024 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1729780484_26451 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Multiple system atrophy is a neurodegenerative disease with α-synuclein aggregation in glial cytoplasmic inclusions, leading to dysautonomia, parkinsonism, and cerebellar ataxia.The aim of this study was to validate the accuracy of the International Parkinson and Movement Disorder Society Multiple System Atrophy clinical diagnostic criteria, particularly considering the impact of the newly introduced brain magnetic resonance imaging (MRI) markers.Diagnostic accuracy of the clinical diagnostic criteria for multiple system atrophy was estimated retrospectively in autopsy-confirmed patients with multiple system atrophy, Parkinson's disease, progressive supranuclear palsy, and corticobasal degeneration.We identified a total of 240 patients. Sensitivity of the clinically probable criteria was moderate at symptom onset but improved with disease duration (year 1: 9%, year 3: 39%, final ante mortem record: 77%), whereas their specificity remained consistently high (99%-100% throughout). Sensitivity of the clinically established criteria was low during the first 3 years (1%-9%), with mild improvement at the final ante mortem record (22%), whereas specificity remained high (99%-100% throughout). When MRI features were excluded from the clinically established criteria, their sensitivity increased considerably (year 1: 3%, year 3: 22%, final ante mortem record: 48%), and their specificity was not compromised (99%-100% throughout).The International Parkinson and Movement Disorder Society multiple system atrophy diagnostic criteria showed consistently high specificity and low to moderate sensitivity throughout the disease course. The MRI markers for the clinically established criteria reduced their sensitivity without improving specificity. Combining clinically probable and clinically established criteria, but disregarding MRI features, yielded the best sensitivity with excellent specificity and may be most appropriate to select patients for therapeutic trials. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. |
| 536 | _ | _ | |a 353 - Clinical and Health Care Research (POF4-353) |0 G:(DE-HGF)POF4-353 |c POF4-353 |f POF IV |x 0 |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 1 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a MRI |2 Other |
| 650 | _ | 7 | |a autopsy‐confirmed |2 Other |
| 650 | _ | 7 | |a brain magnetic resonance imaging |2 Other |
| 650 | _ | 7 | |a multiple system atrophy |2 Other |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Multiple System Atrophy: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Multiple System Atrophy: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Aged |2 MeSH |
| 650 | _ | 2 | |a Middle Aged |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Parkinson Disease: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Magnetic Resonance Imaging: standards |2 MeSH |
| 650 | _ | 2 | |a Magnetic Resonance Imaging: methods |2 MeSH |
| 650 | _ | 2 | |a Retrospective Studies |2 MeSH |
| 650 | _ | 2 | |a Supranuclear Palsy, Progressive: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Sensitivity and Specificity |2 MeSH |
| 650 | _ | 2 | |a Brain: diagnostic imaging |2 MeSH |
| 650 | _ | 2 | |a Brain: pathology |2 MeSH |
| 650 | _ | 2 | |a Aged, 80 and over |2 MeSH |
| 700 | 1 | _ | |a Heine, Johanne |b 1 |
| 700 | 1 | _ | |a Ruf, Viktoria C |b 2 |
| 700 | 1 | _ | |a Compta, Yaroslau |b 3 |
| 700 | 1 | _ | |a Porcel, Laura Molina |b 4 |
| 700 | 1 | _ | |a Troakes, Claire |b 5 |
| 700 | 1 | _ | |a Vamanu, Albert |b 6 |
| 700 | 1 | _ | |a Downes, Sophia |b 7 |
| 700 | 1 | _ | |a Irwin, David |b 8 |
| 700 | 1 | _ | |a Cohen, Jesse |0 0000-0003-2554-5181 |b 9 |
| 700 | 1 | _ | |a Lee, Edward B |b 10 |
| 700 | 1 | _ | |a Nilsson, Christer |b 11 |
| 700 | 1 | _ | |a Englund, Elisabet |b 12 |
| 700 | 1 | _ | |a Nemati, Mojtaba |0 P:(DE-2719)9002938 |b 13 |u dzne |
| 700 | 1 | _ | |a Katzdobler, Sabrina |0 P:(DE-2719)9001160 |b 14 |u dzne |
| 700 | 1 | _ | |a Levin, Johannes |0 P:(DE-2719)2811659 |b 15 |u dzne |
| 700 | 1 | _ | |a Pantelyat, Alex |0 0000-0002-6427-7485 |b 16 |
| 700 | 1 | _ | |a Seemiller, Joseph |b 17 |
| 700 | 1 | _ | |a Berger, Stephen |b 18 |
| 700 | 1 | _ | |a van Swieten, John |b 19 |
| 700 | 1 | _ | |a Dopper, Elise |b 20 |
| 700 | 1 | _ | |a Rozenmuller, Annemieke |b 21 |
| 700 | 1 | _ | |a Kovacs, Gabor G |b 22 |
| 700 | 1 | _ | |a Bendahan, Nathaniel |0 0000-0003-2167-5667 |b 23 |
| 700 | 1 | _ | |a Lang, Anthony E |b 24 |
| 700 | 1 | _ | |a Herms, Jochen |0 P:(DE-2719)2810441 |b 25 |u dzne |
| 700 | 1 | _ | |a Höglinger, Günter |0 P:(DE-2719)2811373 |b 26 |
| 700 | 1 | _ | |a Hopfner, Franziska |0 P:(DE-2719)9003372 |b 27 |u dzne |
| 773 | _ | _ | |a 10.1002/mds.29879 |g Vol. 39, no. 9, p. 1514 - 1522 |0 PERI:(DE-600)2041249-6 |n 9 |p 1514 - 1522 |t Movement disorders |v 39 |y 2024 |x 0885-3185 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/272852/files/DZNE-2024-01270.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/272852/files/DZNE-2024-01270.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:272852 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 0 |6 P:(DE-2719)9003066 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 13 |6 P:(DE-2719)9002938 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 14 |6 P:(DE-2719)9001160 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 15 |6 P:(DE-2719)2811659 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 25 |6 P:(DE-2719)2810441 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 26 |6 P:(DE-2719)2811373 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 27 |6 P:(DE-2719)9003372 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-353 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Clinical and Health Care Research |x 0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 1 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-24 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOVEMENT DISORD : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b MOVEMENT DISORD : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 920 | 1 | _ | |0 I:(DE-2719)1110002 |k AG Höglinger |l Translational Neurodegeneration |x 0 |
| 920 | 1 | _ | |0 I:(DE-2719)1110001 |k AG Herms |l Translational Brain Research |x 1 |
| 920 | 1 | _ | |0 I:(DE-2719)1111015 |k Clinical Research (Munich) |l Clinical Research (Munich) |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1110002 |
| 980 | _ | _ | |a I:(DE-2719)1110001 |
| 980 | _ | _ | |a I:(DE-2719)1111015 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::